Are another 5 years of adjuvant aromatase inhibitor therapy needed?
Qin-Guo Mo*, De-Quan Li*, Jian-Hong Zhong, Chang-Yuan Wei Department of Breast Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, People’s Republic of China *These authors contributed equally to this workIn the recent issue of Breast Cancer: Targets and The...
Guardado en:
Autores principales: | Mo QG, Li DQ, Zhong JH, Wei CY |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c9509be1c44c4aa980562fdec77f0543 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Adjuvant systemic therapy in older women with breast cancer
por: Leone J, et al.
Publicado: (2016) -
Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India
por: Butani D, et al.
Publicado: (2021) -
An Open, Uncontrolled Pilot Study on 12-Week Use of VagiVital for Treatment of Vulvovaginal Atrophy in Breast Cancer Patients Undergoing Adjuvant Aromatase-Inhibitor Therapy
por: Jonasson AF, et al.
Publicado: (2021) -
Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience
por: Li Y, et al.
Publicado: (2020) -
Metastatic breast cancer: Endocrine therapy landscape reshaped
por: Mohamad Adham Salkeni, et al.
Publicado: (2017)